Poland
Industry
BMI View: The acquisition of companies with products outside of normal medical healthcare sales channels will protect Sanofi-Aventis from the tightening of public sector healthcare...
2010-07-22Industry
Pharmaceutical sales patterns in Poland in Q110 showed mixed results, with major contractions on an annual basis in January, followed by a return to strong market growth towards the...
2010-04-14Industry
As part of reforms to Poland's pricing and reimbursement system, the Ministry of Health is considering introducing a 3% tax on returns from reimbursed medicines. The levy would be...
2010-04-13BMI has introduced greater clarity to its core views for the Pharmaceuticals & Healthcare. Short-term core views concern the period through to the end of the 2011-2013 patent cliff,...
2010-03-15Companies
The presence of countries from BMI's Emerging Europe Region in the Pharmaceutical Research and Manufacturers of America (PhRMA)'s Special 301 Submission 2010 remains largely equivalent...
2010-03-11Industry
BMI calculates that Poland's pharmaceutical market grew by 10.5% on a local currency basis in 2009, reaching a value of PLN30.25bn (US$9.85bn) at retail prices. This marks a slightly...
2010-01-12Companies
GlaxoSmithKline (GSK) is to transfer production of benign prostatic hyperplasia treatment Avodart (dutasteride) from France to Poland, in an effort to optimise manufacturing costs....
2010-01-11Industry
Poland's pricing and reimbursement system is similar in structure to many others in Central and Eastern Europe (CEE), but among the most rigorous in terms controlling expenditure....
2010-01-06
